康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

休市中 08-07 16:08:13

100.000

+3.950

+4.11%

最高101.400	最低95.250	成交量911.96万
今开95.500	昨收96.050	日振幅6.40%
总市值921.00亿	流通市值921.00亿	总股本9.21亿
成交额9.02亿	换手率0.99%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":100,"timestamp":1786090093010,"preClose":96.05,"halted":0,"volume":9119553,"delay":0,"changeRate":0.04112441436751695,"floatShares":921000000,"shares":921000000,"eps":-1.4340377612697766,"marketStatus":"休市中","change":3.95,"latestTime":"08-07 16:08:13","open":95.5,"high":101.4,"low":95.25,"amount":902402078,"amplitude":0.064029,"askPrice":100.3,"askSize":9000,"bidPrice":100,"bidSize":77000,"shortable":3,"etf":0,"ttmEps":-1.4340377612697766,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":96.05,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":1.457591409016315,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.649,"impliedVolPercentile":0.5852},"requestUrl":"/m/hq/s/09926/tweets","defaultTab":"tweets","newsList":[{"id":"2657697002","title":"ETF异动 | 南方恒生生科(03174)涨超5% 创新药龙头业绩集中爆发 全球产业链景气度维持高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2657697002","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657697002?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:56","pubTimestamp":1786085810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，南方恒生生科涨超5%，截至发稿，涨5.4%，报3.628港元，成交额723.74万港元。百济神州上半年归母净利润达32.71亿元，同比增长627.1%，并上调全年营收预期。信达生物上半年产品收入同比增长超过55%，该公司综合产品线保持强劲增长。兴业证券表示，全球创新药及产业链景气度维持高位，多家海外MNC与CXO披露中报盈喜并上调2026年全年指引，验证全球创新药研发投入与产业链需求仍处于较高景气区间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","KURE","LU0348825331.USD","LU0051755006.USD","BK4585","06978","09926","LU2476274720.SGD","06160","LU0181495838.USD","LU0320764599.SGD","LU3063872942.SGD","159992","LU2097828474.EUR","BK1587","LU0708995583.HKD","BK4588","LU1242518857.USD","IE00B0JY6N72.USD","LU1770034418.SGD","LU1720050803.USD","LU0516422366.SGD","03174","LU1719994722.HKD","MEDX","BK4550","LU0823426480.USD","IBBQ","01801","FDN","02269","LU1251922891.USD","BK1583","LU0348827113.USD","LU0455707207.USD","LU0502904849.HKD","LU0540923850.HKD","LU2125910500.SGD","BK1521","SG9999002562.SGD","LU0348767384.USD","BK1500","LU2399975544.HKD","LU0456827905.SGD","02359","LU0348766576.USD","LU1046422090.SGD","LU1961090484.USD","LU0572944931.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160076722","title":"异动解读｜康方生物盘中上涨3.28%，依沃西联合维恩妥尤单抗一线治疗UC国际注册研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1160076722","media":"行情直击","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160076722?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:03","pubTimestamp":1786078994,"startTime":"0","endTime":"0","summary":"8月7日，康方生物盘中上涨3.28%，报99.2港元，成交额3.84亿港元。消息面上，公司海外合作伙伴Summit近日宣布启动依沃西联合维恩妥尤单抗头对头帕博利珠单抗联合维恩妥尤单抗一线治疗局部晚期或转移性尿路上皮癌的国际II/III期注册性临床研究。该研究是依沃西第16项注册性/III期临床、第6项国际多中心注册性研究，也是公司IO2.0+ADC2.0战略在泌尿肿瘤领域的关键布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物盘中上涨3.28%，依沃西联合维恩妥尤单抗一线治疗UC国际注册研究启动","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160066686","title":"康方生物更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1160066686","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160066686?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:26","pubTimestamp":1786008381,"startTime":"0","endTime":"0","summary":"康方生物于2026年8月6日发布截至2026年7月31日的证券变动月报表。报告显示，公司注册股本维持在5,000,000,000股普通股，每股面值0.00001美元，注册股本总额为50,000美元，与上月无差异。本月末，公司已发行普通股数量为921,143,176股，库藏股数量为0股，已发行股份总数与上月底保持一致。在购股权计划方面，2022年6月28日采纳并于2024年6月30日获修订的首次公开发售后购股权计划于本月内新授出的股份期权数量为3,603,500，累计使得本月底结存的股份期权总数上升至10,889,500。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544712","title":"康方生物：依沃西联合辉瑞维恩妥尤单抗一线治疗UC国际II/III期研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544712","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657544712?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:28","pubTimestamp":1785932889,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0321505868.SGD","LU0321505439.SGD","LU2399975544.HKD","SG9999002224.SGD","LU1894683264.USD","IE00BLSP4239.USD","LU2476274308.USD","LU0348783233.USD","LU0634319403.HKD","LU1883839398.USD","LU0417516738.SGD","LU1720050803.USD","BK4550","LU0122379950.USD","BK4592","LU0225771236.USD","SGXZ57979304.SGD","LU0058720904.USD","SG9999001176.SGD","IE00BBT3K403.USD","09926","BK4588","IE00B19Z3581.USD","LU0234572021.USD","LU0417516902.SGD","LU0540923850.HKD","IE00BLSP4452.SGD","BK4007","LU1057294990.SGD","LU0348766576.USD","LU0348735423.USD","IE000M9KFDE8.USD","BK4568","LU0348825331.USD","LU1894683348.USD","LU1961090484.USD","SG9999002232.USD","SG9999011175.SGD","BK1574","LU1066053197.SGD","BK1161","PFE","LU0225284248.USD","LU1066051498.USD","LU0985481810.HKD","LU0170899867.USD","KURE","OZEM","IE0002270589.USD","SG9999013999.USD","LU0561508036.HKD","BK4534","LU0868494617.USD","LU1794554557.SGD","LU0348784397.USD","BK4599","LU0348827113.USD","LU0289739699.SGD","BK4533","LU2488822045.USD","BK4581","LU2778985437.USD","LU0417516571.SGD","LU0306807586.USD","LU0456855351.SGD","IE00BPRC5H50.USD","SG9999001176.USD","LU0306806265.USD","LU2596442595.SGD","BK4585","LU2476274720.SGD","IE00B3T34201.USD","SG9999003800.SGD","LU0348767384.USD","IE00B543WZ88.USD","LU1023059063.AUD","IE00B5MMRT66.SGD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163842020","title":"异动解读｜康方生物盘中上涨3.04%，创新药板块集体走强带动","url":"https://stock-news.laohu8.com/highlight/detail?id=1163842020","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163842020?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:58","pubTimestamp":1785913139,"startTime":"0","endTime":"0","summary":"8月5日，康方生物盘中上涨3.04%，报96.7港元，成交额3.92亿港元。消息面上，创新药板块集体走强，同行业信达生物涨5.02%、康诺亚-B涨3.88%、百济神州涨3.25%。此外，下半年WCLC、ESMO等学术会议密集召开，核心管线数据披露预期持续催化板块情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物盘中上涨3.04%，创新药板块集体走强带动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188918124","title":"异动解读｜康方生物盘中下跌3.29%，股权激励行使价倒挂叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1188918124","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188918124?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:23","pubTimestamp":1785381801,"startTime":"0","endTime":"0","summary":"7月30日，康方生物盘中下跌3.29%，报92.5港元/股，成交额3.23亿港元。消息面上，公司于7月26日公告向167名承授人授出360.35万份购股权，行使价99.50港元，同时向162名承授人授出164.85万个受限制股份单位。此前公司因依沃西全球III期OS数据更新于7月23日大涨近6%后，已连续多个交易日回调。康方生物是一家致力于研究、开发、生产及商业化抗体药物的公司，在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域，核心产品包括依沃西等。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物盘中下跌3.29%，股权激励行使价倒挂叠加生物科技板块集体走弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","LU0051755006.USD","KURE","BK1610","161027","LU2242644610.SGD","02142","01093","BK1564","BK1574","09688","LU0067412154.USD","LU0307460666.USD","02611","LU0052750758.USD","LU0417516738.SGD","LU0588546209.SGD","BK1141","601211","06160","IE00B543WZ88.USD","KCE","LU0348784397.USD","02269","BK1588","06185","01801","BK1583","LU2476274308.USD","LU0634319403.HKD","LU0181495838.USD","02616","LU0561508036.HKD","LU0359202008.SGD","LU1720050803.USD","SG9999002463.SGD","LU1328277881.USD","IE00B0JY6N72.USD","LU1008478684.HKD","LU1719994722.HKD","IE00B5MMRT66.SGD","01177","01877","09926","LU1251922891.USD","09995","BK1147","HK0000165453.HKD","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145088057","title":"异动解读｜康方生物盘中下跌3.04%，股权激励落地叠加生物科技板块整体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1145088057","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145088057?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:46","pubTimestamp":1785206771,"startTime":"0","endTime":"0","summary":"7月28日，康方生物盘中下跌3.04%，报95.6港元/股，成交额1.79亿港元。消息面上，公司于7月26日公告根据购股权计划向167名承授人授出360.35万份购股权，行使价99.50港元，同时向162名承授人授出164.85万个受限制股份单位。当前股价已跌破行使价，短期市场对潜在摊薄存在情绪压力。此前公司因依沃西全球III期OS数据更新于7月23日大涨近6%后，已连续回调三个交易日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物盘中下跌3.04%，股权激励落地叠加生物科技板块整体回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU2399975544.HKD","LU0634319403.HKD","09996","LU0588546209.SGD","02096","06996","LU0348783233.USD","LU0856984785.SGD","06078","09926","LU2039709279.SGD","09966","01177","02162","02269","BK1521","06990","02596","BK1219","BK1587","LU1813983027.USD","02273","159938","LU1720050803.USD","KURE","03692","01276","01951","LU2476274308.USD","01548","00013","LU2097828714.EUR","HK0000165453.HKD","LU2328871848.SGD","01093","01801","HK0000320223.HKD","02268","09939","KCE","03329","03759","01530","01952","06821","LU0572944931.SGD","LU1880383366.USD","LU0417516571.SGD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192875709","title":"康方生物（09926）授出360.35万份购股权及164.85万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1192875709","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192875709?lang=zh_cn&edition=full","pubTime":"2026-07-26 20:06","pubTimestamp":1785067573,"startTime":"0","endTime":"0","summary":"2026年7月26日，康方生物公告，于2026年7月24日根据公司购股权计划及2021年受限制股份单位计划向董事及员工授出购股权与受限制股份单位，旨在认可现有人才贡献并强化激励与长期留任。本次共向167名承授人授出3,603,500份购股权，其中7名为董事，160名为公司非关联雇员。购股权行使价为每股99.50港元，高于授出日前五个营业日平均收市价95.60港元，并等同于授出当日收市价。每名承授人接纳购股权时须支付1港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654666670","title":"康方生物(09926)授出360.35万份购股权及164.85万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2654666670","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654666670?lang=zh_cn&edition=full","pubTime":"2026-07-26 19:55","pubTimestamp":1785066925,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物(09926)公布，于2026年7月24日，公司根据购股权计划向167名承授人授出360.35万份购股权，每份购股权行使价为99.5港元。同日，公司根据2021年受限制股份单位计划向162名承授人授出164.85万个受限制股份单位，惟须待承授人接纳后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348766576.USD","LU0540923850.HKD","KURE","BK1161","LU0348827113.USD","LU0634319403.HKD","LU0417516571.SGD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2778985437.USD","LU0348783233.USD","LU0417516738.SGD","LU2476274308.USD","LU2488822045.USD","BK1574","LU0348825331.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU2399975544.HKD","09926","LU2476274720.SGD","IE00B543WZ88.USD","LU0348784397.USD","LU0417516902.SGD","LU1720050803.USD","LU0348767384.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186148266","title":"异动解读｜康方生物盘中下跌3.11%，连续两日大涨后获利回吐叠加板块回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1186148266","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186148266?lang=zh_cn&edition=full","pubTime":"2026-07-24 13:22","pubTimestamp":1784870521,"startTime":"0","endTime":"0","summary":"7月24日，康方生物盘中下跌3.11%，报99.6港元/股，成交额4.5亿港元。板块方面，生物科技行业今日整体偏弱，荣昌生物跌3.78%，三生制药跌2.11%，科伦博泰生物跌0.96%，信达生物跌0.49%，仅百济神州逆势涨3.3%，板块回调形成共振压力。基本面上，依沃西跨人种疗效一致性已获验证，数据已提交FDA支持BLA审评，中长期全球注册价值未发生变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770805","title":"壹评级：康方生物依沃西数据更新，创新药双抗赛道确定性提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770805","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653770805?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:13","pubTimestamp":1784855598,"startTime":"0","endTime":"0","summary":"康方生物海外合作伙伴Summit更新了依沃西全球Ⅲ期HARMONi研究的生存数据，西方患者总生存风险比改善至0.76。第一财经“壹评级”认为，该数据实质性回应了市场对中国创新药海外适用性的核心质疑，跨人种疗效一致性得到验证，该药物的全球注册价值进一步凸显。“壹评级”指出，随访延长带来的风险比持续优化，体现了免疫治疗的拖尾效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607243819804714.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607243819804714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09926","159992","06978","IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131916151","title":"港股直击 | 创新药板块走高，康方生物涨近7%，康诺亚-B、荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131916151","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131916151?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:46","pubTimestamp":1784785579,"startTime":"0","endTime":"0","summary":"7月23日，创新药板块走高，康方生物涨近7%，康诺亚-B、荣昌生物涨超3%，恒瑞医药、药明康德涨超2%，药明生物涨近2%。消息面上，康诺亚-B公告称，公司重点研发产品CM512（TSLP/IL-13双抗）已被国家药监局药审中心纳入突破性治疗品种名单，拟用于治疗慢性鼻窦炎伴鼻息肉。CM512为公司自主研发的IgG-like长效型TSLPxIL-13双阻断剂，此前I期临床研究已于2025年11月达成全部研究终点，并于2026年4月在《Journal of Translational Medicine》发表相关结果。目前，CM512用于慢性鼻窦炎伴鼻息肉的II期临床研究正在推进，公司同时布局中重度哮喘、中重度慢阻肺、成人中重度特应性皮炎、慢性自发性荨麻疹等多个适应症。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","09995","09926","02269","02359","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653713988","title":"港股异动 | 康方生物(09926.HK)涨近6% 依沃西全球III期HARMONi 研究OS更新 东西方人群疗效高度一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2653713988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653713988?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:38","pubTimestamp":1784777931,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0561508036.HKD","LU0634319403.HKD","LU2476274720.SGD","LU0417516902.SGD","LU1961090484.USD","LU2488822045.USD","LU0348735423.USD","LU0417516738.SGD","09926","LU0348827113.USD","LU2778985437.USD","LU1720050803.USD","LU0417516571.SGD","LU0348825331.USD","BK1161","LU2399975544.HKD","LU0348783233.USD","IE00B543WZ88.USD","LU1794554557.SGD","KURE","LU2476274308.USD","LU0348767384.USD","IE00B5MMRT66.SGD","BK1574","LU0348766576.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153583800","title":"异动解读｜康方生物盘中上涨4.15%，依沃西全球III期OS数据持续改善叠加肾癌新合作落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1153583800","media":"行情直击","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153583800?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:04","pubTimestamp":1784775845,"startTime":"0","endTime":"0","summary":"7月23日，康方生物盘中上涨4.15%，报103.0港元/股，成交额3.36亿港元。核心驱动方面，公司海外合作伙伴Summit Therapeutics近日公布依沃西全球多中心III期HARMONi研究最新OS分析：ITT人群及西方人群OS HR均改善至0.76，与中国HARMONi-A研究高度一致，数据已提交FDA支持BLA审评。同日，Summit宣布与Arcus Biosciences达成合作，将推进依沃西联合HIF-2α抑制剂casdatifan治疗肾透明细胞癌的国际多中心临床研究，进一步拓展依沃西适应症版图。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145405224","title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145405224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145405224?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:11","pubTimestamp":1784686287,"startTime":"0","endTime":"0","summary":"7月22日，港股生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%，复宏汉霖、药明康德、君实生物涨超2%。消息面上，美国总统特朗普当地时间7月21日在社交媒体发文表示，自2026.8.1起，所有进口到美国的仿制药将在未来两年内继续适用零关税。两年期满后，相关产品将被征收100%的关税，期限为一年。此后，关税将进一步提高至200%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","02359","01877","03347","09926","02696","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176289671","title":"异动解读｜康方生物盘中上涨4.39%，新型双抗ADC临床推进叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1176289671","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176289671?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:42","pubTimestamp":1784684554,"startTime":"0","endTime":"0","summary":"7月22日，康方生物盘中上涨4.39%，报100.2港元/股，成交额2.31亿港元。消息面上，公司近日宣布新型Trop2/Nectin-4双特异性ADC联合依沃西单抗治疗晚期非小细胞肺癌的II期临床研究完成首例患者给药，标志其\"IO2.0+ADC2.0\"双平台战略进入关键推进阶段。同时，生物科技板块今日整体走强，荣昌生物涨3.81%，三生制药涨2.96%，信达生物涨2.12%，百济神州涨1.76%，板块共振提供额外支撑。此外，多家券商近期维持公司\"买入\"评级，中信建投指其凭借Tetrabody双抗技术平台具备全球竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137883360","title":"异动解读｜康方生物盘中下跌3.05%，报90.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137883360","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137883360?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:13","pubTimestamp":1784600024,"startTime":"0","endTime":"0","summary":"7月21日，康方生物盘中下跌3.05%，报90.5港元/股，成交额1.88亿港元。康方生物所在的生物科技行业中，板块整体表现偏弱，个股中，百济神州跌2.14%，信达生物跌2.22%，科伦博泰生物跌0.79%，三生制药跌2.24%，荣昌生物跌3.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179328618","title":"康方生物在新型Trop2/Nectin-4双特异性ADC（AK146D1）联合依沃西单抗治疗晚期非小细胞肺癌的II期研究中完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1179328618","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179328618?lang=zh_cn&edition=full","pubTime":"2026-07-20 13:33","pubTimestamp":1784525593,"startTime":"0","endTime":"0","summary":"康方生物宣布，其新型Trop2/Nectin-4双特异性抗体偶联药物（AK146D1）与依沃西单抗联合用于治疗晚期非小细胞肺癌的II期临床研究，已完成首例患者给药。这项研究旨在评估该联合疗法在此类患者中的安全性与初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0348827113.USD","LU1720050803.USD","LU2488822045.USD","LU0540923850.HKD","LU0634319403.HKD","LU0561508036.HKD","LU0348783233.USD","LU0348825331.USD","LU1794554557.SGD","LU0348735423.USD","LU1961090484.USD","LU0417516902.SGD","BK1574","LU0417516571.SGD","LU0417516738.SGD","LU0348766576.USD","IE00B543WZ88.USD","09926","LU2476274308.USD","LU0348784397.USD","BK1161","IE00B5MMRT66.SGD","LU2399975544.HKD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0644},{"period":"1month","weight":0.0363},{"period":"3month","weight":-0.2537},{"period":"6month","weight":-0.0089},{"period":"1year","weight":-0.3647},{"period":"ytd","weight":-0.115}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.571429,"avgChangeRate":0.002553},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}